Advanced Bifurcation Systems Appoints Industry Veteran Thomas O’Neill to Board of Directors

Advanced Bifurcation Systems Appoints Industry Veteran Thomas O’Neill to Board
of Directors

Founding Principal of Sandler O'Neill to Bring Deep Financial Services
Expertise and World-Class Relationships to ABS

LOS ANGELES, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems
(“ABS” or the “Company”), a clinical stage medical device company developing
an innovative stenting platform which overcomes the limitations of current
approaches for the treatment of bifurcation lesions in coronary angioplasties,
today announced the addition of Thomas O’Neill to the Board of Directors.

Mr. O'Neill is an industry veteran who brings more than 30 years of Board and
executive-level experience in the financial markets and medical devices to
ABS. During his distinguished financial career, Mr. O’Neill was a founder of
Sandler O’Neill + Partners and headed up practice groups for notable financial
institutions including Rothschild and Bear Stearns. He also amassed extensive
Board-level experience for institutions such as Nasdaq and First Allied, and
has valuable industry expertise having been an Independent Director at medical
device company, Misonix, for over a decade.

Mr. O’Neill currently serves as Co-Chairman of First Empire, a U.S. broker
dealer. He has served as an Independent Director of Bank Financial Corp. since
2012 and is a Director at Crypto Metrics. Previously, Mr. O’Neill was as an
Independent Director at Archer Daniels Midland Company from 2004 until 2016,
and The Nasdaq OMX Group, Inc. (now Nasdaq, Inc.) from 2003 to 2015. He also
served as Director of The NASDAQ Stock Market LLC and as an Independent
Director at Misonix, a medical device company, from 2003 until 2015.

"We are thrilled to have Tom join the ABS team. As a financial services
industry veteran, he brings deep industry knowledge and financial market
relationships to ABS. In addition, his experience in medical devices makes
Thomas particularly well-qualified to join our Board. Tom is a sought-after
advisor and we look forward to his contributions as we work to achieve our
corporate goals," said Charles Laverty, CEO of Advanced Bifurcation Systems.

In earlier roles, Mr. O’Neill co-founded investment bank Sandler O'Neill +
Partners in 1988 and remained with the firm through 2010. He also served as a
Managing Director and Co-Manager of Bear Stearns and as its Co-Manager of the
Financial Services Group from 1985-1988. He previously acted as Chairman of
the holding company of First Allied, a U.S. broker-dealer. Mr. O’Neill joined
Ranieri Partners in 2010 as the Chairman of the Financial Services Group. He
began his career at L.F. Rothschild & Co. and served as Managing Director of
the Bank Service Group at Rothschild from 1983 to 1988.

"I am excited to join ABS at this important juncture in the Company's growth
trajectory, as it prepares to apply for FDA-approval," said Mr. O’Neill.
"Advanced Bifurcation is an innovative leader and I believe could deliver
significant strides in coronary treatments through its unique patented
technology. I look forward to working with the team to achieve ABS’s financial
and strategic objectives."

Mr. O’Neill is a veteran of the United States Air Force and a graduate of New
York University.

ABS has created an innovative new stenting platform designed to treat
bifurcation lesions in coronary patients. Current methods are complex and
unreliable, but the ABS platform has simplified the process and it is hoped
that their method with become the standard of care and reduce the number of
open-heart surgeries.

Mr. O’Neil is the latest senior executive to join the ABS team. In the last
six months, the Company has secured additional funding and added an
experienced group of professionals to its leadership team. Mr. Scott King has
been appointed as Chief Compliance Officer, Mr. Ken Richards has joined the
organization as Chief Financial Officer, and Mr. Drew Foster has been named
Vice President of Global Business Development.

About Advanced Bifurcation Systems

Advanced Bifurcation  Systems  (“ABS”)  is a  clinical  stage  medical  device 
company developing an innovative stenting platform for simple treatment of all
bifurcation lesions  in  coronary angioplasties.  ABS  has developed  a  novel 
technology  which  overcomes  the  limitations  of  current  approaches  while 
simplifying the  procedure. The  Company’s groundbreaking  system consists  of 
numerous differentiating features,  including a  unique modular  independently 
movable dual-catheter system for provisional  side-branch stenting as well  as 
full bifurcation stenting with a proprietary crimping technology allowing  for 
partial  crimping  of   the  main   stent.   For  more   information,  go   to


Advanced Bifurcation Systems
Charles Laverty
Chief Executive Officer
(949) 432-4824

Primary Logo
Press spacebar to pause and continue. Press esc to stop.